Skip to content

Clinical Study on the Treatment of Ovarian Failure with Stromal Vascular Fraction (SVF) Derived from Autologous Fat

Clinical Study on the Treatment of Ovarian Failure with Stromal Vascular Fraction (SVF) Derived from Autologous Fat

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500100897
Enrollment
Unknown
Registered
2025-04-16
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian failure

Interventions

Treatment group:In-situ injection of SVF into the ovary

Sponsors

The First Affiliated Hospital of Xiamen University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
16 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1.Female subjects aged between 16 and 55 years old. 2.The duration of amenorrhea is more than six months and less than two years. 3.With an interval of more than 4 weeks, the follicle-stimulating hormone (FSH) level is greater than 40 U/L for two consecutive times. 4.The average diameter of each ovary was > 10mm; 5.Agreed to sign an informed consent form;

Exclusion criteria

Exclusion criteria: 1.Subjects tested positive for either treponema pallidum, HIV, hepatitis B virus or hepatitis C virus; 2.Abnormal blood clotting function, can not receive liposuction surgery or ovarian injection in situ; 3.Subjects with allergic predisposition; 4.Liver, heart, kidney and other important organs are not fully functional; (According to the diagnostic criteria of the tenth edition of Internal Medicine, the cardiac function rating (NYHA rating) is greater than or equal to grade II. The staging of renal function based on glomerular filtration rate and serum creatinine level is greater than or equal to the second stage. Liver function ALT, AST and bilirubin are more than or equal to 2 times the upper limit of standard value. 5.History of malignant tumors; 6.Treatment with growth hormone and/or estrogen-progestin for three months prior to treatment; 7.Participate in other clinical studies within three months prior to treatment; 8.There are autoimmune diseases or other serious medical and surgical diseases; 9.Abnormal chromosome karyotype; 10.Family history of severe genetic disorders; 11.Inability to follow up on treatment, follow-up, or refusal to participate in post-operative interviews; 12.Patients deemed ineligible for inclusion by the investigator;

Design outcomes

Primary

MeasureTime frame
LH,E2,FSH,P,T,PRL;Hemodynamic indicators within the ovary;ATM;The restoration of menstruation;

Countries

China

Contacts

Public ContactQionghua Chen

The First Affiliated Hospital of Xiamen University

Cqhua616@126.com+86 592 2139807

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026